<i>KRAS</i> Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer

<i>KRAS</i> Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer

There is an urgent need to identify new predictive biomarkers for treatment response to both platinum doublet chemotherapy (PT) and immune checkpoint blockade (ICB). Here, we evaluated whether treatment outcome could be affected by <i>KRAS</i> mutational status in patients with metastati...

Full description

Bibliographic Details
Main Authors: Ella A. Eklund, Clotilde Wiel, Henrik Fagman, Levent M. Akyürek, Sukanya Raghavan, Jan Nyman, Andreas Hallqvist, Volkan I. Sayin
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
lung cancer
<i>KRAS</i>
chemotherapy
immunotherapy
biomarker
Online Access:https://www.mdpi.com/2072-6694/14/9/2063

Internet

https://www.mdpi.com/2072-6694/14/9/2063

Similar Items